KALA BIO Q1 net loss $8.9M; cash $42.2M; KPI-012 Phase 2b topline data due Q3 2025

KALA BIO, Inc.

2025-Q1 EPS reported -$1.41 vs consensus -$103.53 ▲ beat (+98.6%)

Cash and cash equivalents of $42.2M as of March 31, 2025, expected to fund operations into Q1 2026.
Q1 2025 net loss $8.9M ($1.41 per diluted share) vs $11.8M ($4.20) prior year; operating loss $10.7M.
G&A $4.6M (down from $5.4M); R&D $6.1M (down from $6.4M). Weighted shares 6.3M vs 2.8M.
Phase 2b CHASE trial of KPI-012 in PCED continues enrolling; topline data anticipated in Q3 2025.
Exploring KPI-012 for Limbal Stem Cell Deficiency; preclinical KPI-014 for inherited retinal diseases.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001558370-25-007664
form_type: 8-K
ticker: KALA
cik: 0001479419
company_name: KALA BIO, Inc.
filed_at: 2025-05-14T23:59:59+00:00
discovered_at: 2026-05-14T18:02:48.419655+00:00
generated_at: 2026-05-21T08:24:04.698024+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001558370-25-007664
json_url: https://secwatch.observer/filing/0001558370-25-007664.json
markdown_url: https://secwatch.observer/filing/0001558370-25-007664.md
text_url: https://secwatch.observer/filing/0001558370-25-007664.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/0001558370-25-007664-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837025007664/kala-20250514x8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001558370-25-007664

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.